Navigation Links
Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City
Date:3/30/2011

BASKING RIDGE, N.J., March 30, 2011 /PRNewswire/ -- Regado Biosciences, a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Needham & Company's 10th Annual Healthcare Conference at the New York Palace Hotel in New York City on Wednesday, April 6, 2011 at 11:20 a.m. EDT.  The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system REG1, including a summary of the REG1 phase 2b trial (RADAR) results.

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent.  This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its compleme
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
10. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  On July 31, ... to Congress that it is moving forward to regulate ... the minutes until laboratories throughout the U.S. will need ... Although some medical laboratories may subscribe to the ... FDA to put guidelines in place, it,s widely acknowledged ...
(Date:9/2/2014)... 2, 2014  Reportlinker.com announces that a new market ... Chinese and Taiwanese Markets for Minimally Invasive Spinal ... The market for MIS spinal devices in ... is growing at a fast pace, albeit at different ... happening in China , where MIS ...
(Date:9/2/2014)... The Pharmaceutical Care Management Association (PCMA), the ... filed a lawsuit in Iowa ... law that restricts tools used by PBMs ... and consumers.  The law—HF 2297—forces PBMs ... use of Maximum Allowable Cost (MAC) lists that keep ...
Breaking Medicine Technology:FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 2Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 4Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 5Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 6Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 7Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 8Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 9Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2
... Double-Blind Study Targets Biomarker-Defined Population, BERKELEY ... GNTA ) announced that the first ... Phase 3 trial of Genasense,(oblimersen sodium) Injection ... is a randomized, double-blind, placebo-controlled study in ...
... Editor-in-Chief of New Brain Stimulation Journal, CHARLESTON, ... (MUSC) today announced the results of a functional ... Nerve Stimulation) Therapy(TM),for patients with treatment-resistant depression (TRD). ... MUSC Department of Psychiatry,appears in the August 2007 ...
Cached Medicine Technology:Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression 2New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression 3
(Date:9/2/2014)... 2014 Becker's Healthcare is excited ... Program on October 23-25, 2014 at the Swissotel ... - The Business and Operations of ASCs brings ... continuing education, networking events, and an exhibit hall ... Outstanding educational offerings throughout the three-day event, The ...
(Date:9/2/2014)... BOSTON (September 2, 2014 4 pm EDT): In a ... American Medical Association , a team of Boston researchers ... improve dietary quality in the United States. The researchers ... at Tufts University, Harvard University and Boston Children,s Hospital ... subsidizing healthier foods could both help people make meaningful ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Cloud Medical ... of “Cloud Based” Medical Practice Business Operations solutions and ... of Digital Cyber Security solutions for all industries announced ... on the trading floor of the CME in Chicago ... DeLaGarza stated that we are very proud of the ...
(Date:9/2/2014)... by radiation therapy survived as long as patients ... study conducted by researchers at the Stanford University ... of California. , The comprehensive analysis of nearly ... first to directly compare survival rates following the ... removal of both breasts), unilateral mastectomy (the removal ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Medex ... location of their corporate headquarters in Coral Springs, Fla. ... have exceeded our business development objectives for the 2014 ... Neil Herbst. “Our industry has requested a higher level ... utilization reviews. Medex has delivered, and the industry has ...
Breaking Medicine News(10 mins):Health News:Becker's Healthcare Announces Ambulatory Surgery Center Educational Program 2Health News:Becker's Healthcare Announces Ambulatory Surgery Center Educational Program 3Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 4Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2
... Nov. 25 Thanksgiving meals will be delivered to approximately ... to Faith In Action/Volunteer Action for Aging, a program operated ... Plan. For more than 17 years these organizations have gathered ... in need in Long Beach, Lakewood, Signal Hill, South Bay, ...
... LOS ANGELES, Nov. 25 The Black AIDS Institute recently ... 2010. , The new Board Members are a highly diverse ... government health programs, editorial, and business entrepreneurship. The Board also ... heterosexual and gay Black men and women, some living with ...
... Broad Political Endorsements, Business, and Press Join Effort to ... again, the National Bipolar Foundation and the MedicAlert Foundation receive ... now being widely accepted as a preventive health care measure ... proclamation of endorsement via Federal Express Priority Mail from the ...
... have found evidence of a statistically significant survival ... receptor (ER)-positive tumors had high levels of phosphorylation ... a brief communication published online November 25 in ... . Approximately 50% of breast carcinomas are ...
... pressure? This simple question has been the focus of ... High Blood Pressure in Mice & Men, Does stress increase ... of intense research for many years. Now new research ... novel gene, phosducin, and the blood pressure response to stress ...
... Rituximab, already used to fight rheumatoid arthritis, could help ... (HealthDay News) -- A drug commonly used to treat ... promise in helping patients newly diagnosed with type 1 ... producing some of their own insulin, even though the ...
Cached Medicine News:Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 4Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
... As a pioneer in the design and ... extraction of viscous fluids, D.O.R.C. is pleased ... combination of injection and extraction in one ... controlled injection of viscous fluids, such as ...
... both 96- and 384-well plates and ... Washer. As a self contained and ... full control of precise fluidic delivery ... simple squeeze bottle to the full ...
The EL401 Manual Plate/Strip Washer accommodates all 96-well microplates and microwell strips. The unique alignment mechanism allows quick and accurate positioning of the 8- or 12-channel manifold ab...
Medicine Products: